Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

Discover key takeaways from Phillips 66's Q2 2025 earnings call, highlighting record refining utilization, improved financial results, and strategies ...